In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Relay Therapeutics Inc’s stock clocked out at $6.05, down -7.35% from its previous closing price of $6.53. In other words, the price has decreased by -$7.35 from its previous closing price. On the day, 4.99 million shares were traded. RLAY stock price reached its highest trading level at $6.7 during the session, while it also had its lowest trading level at $6.015.
Ratios:
To gain a deeper understanding of RLAY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.14 and its Current Ratio is at 19.14. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $4.
Jefferies Upgraded its Hold to Buy on September 10, 2024, whereas the target price for the stock was revised from $10.60 to $16.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 03 ’25 when Patel Sanjiv sold 62,073 shares for $7.00 per share. The transaction valued at 434,511 led to the insider holds 703,215 shares of the business.
Rahmer Peter sold 21,394 shares of RLAY for $160,455 on Oct 29 ’25. The insider now owns 337,469 shares after completing the transaction at $7.50 per share. On Oct 28 ’25, another insider, Rahmer Peter, who serves as the insider of the company, sold 19,135 shares for $7.29 each. As a result, the insider received 139,494 and left with 358,863 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1048600448 and an Enterprise Value of 485498432. For the stock, the TTM Price-to-Sale (P/S) ratio is 125.43 while its Price-to-Book (P/B) ratio in mrq is 1.72. Its current Enterprise Value per Revenue stands at 58.109 whereas that against EBITDA is -1.515.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.53, which has changed by -0.017857134 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $7.64, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 9.06%, while the 200-Day Moving Average is calculated to be 54.57%.
Shares Statistics:
It appears that RLAY traded 1.70M shares on average per day over the past three months and 2412960 shares per day over the past ten days. A total of 172.63M shares are outstanding, with a floating share count of 131.00M. Insiders hold about 24.46% of the company’s shares, while institutions hold 75.89% stake in the company. Shares short for RLAY as of 1760486400 were 21928192 with a Short Ratio of 12.88, compared to 1757894400 on 22504700. Therefore, it implies a Short% of Shares Outstanding of 21928192 and a Short% of Float of 15.43.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of Relay Therapeutics Inc (RLAY).The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.38 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.72 and -$2.08 for the fiscal current year, implying an average EPS of -$1.86. EPS for the following year is -$1.74, with 7.0 analysts recommending between -$1.24 and -$2.67.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for RLAY’s current fiscal year. The highest revenue estimate was $12.95M, while the lowest revenue estimate was $8.36M, resulting in an average revenue estimate of $8.96M. In the same quarter a year ago, actual revenue was $10.01M
